WYETH CORDARONE WILL BE $150 MIL. DRUG "SHORTLY", AHP SAYS; NEW CLINICAL TRIAL DATA WILL SUPPORT APPLICATION FOR PREVENTION OF ARRHYTHMIC DEATH INDICATION
Executive Summary
Wyeth-Ayerst's anti-arrhythmic Cordarone is "going to go over the $150 mil. mark very shortly," American Home Products Exec VP Fred Hassan reported at AHP's R&D day in Pearl River, N.Y. March 28.